Evain-Brion Danièle, Berveiller Paul, Gil Sophie
Therapie. 2014 Jan-Feb;69(1):3-11. doi: 10.2515/therapie/2014002. Epub 2014 Apr 4.
With more than 830,000 live births in France, a great number of pregnant women are concerned by a treatment during pregnancy and many questions revolve around appreciating medication-related risks during pregnancy. The human placenta is the interface between mother and fetus and remains difficult to study for ethical reasons. Placental transfer of drugs from mother to fetus is dependent on their physicochemical properties, maternal and fetal factors and placental factors. The human placental perfusion model is the only experimental model to study human placental transfer of drugs in organized placental tissue. In vitro models utilizing cell cultures are mostly limited to the investigation of cellular toxicity along pregnancy or specific transfer mechanisms, such as their interaction with transporters. Taking advantage of the complementarity of these models, it will be possible to develop a rational use of drugs during this period.
在法国，每年有超过83万例活产，大量孕妇会在孕期接受治疗，许多问题都围绕着评估孕期用药风险展开。人类胎盘是母亲与胎儿之间的界面，出于伦理原因，其研究仍然困难重重。药物从母亲向胎儿的胎盘转运取决于药物的物理化学性质、母体和胎儿因素以及胎盘因素。人胎盘灌注模型是研究有组织胎盘组织中药物人胎盘转运的唯一实验模型。利用细胞培养的体外模型大多仅限于研究孕期的细胞毒性或特定转运机制，比如它们与转运蛋白的相互作用。利用这些模型的互补性，在此期间合理用药将成为可能。
